Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL162109 | 0.98 | GSK3B (0.65) | GSK3BTSHRCES1CA1CA2 | |
| Hydrochloric Acid SCHEMBL15057783 | 0.96 | GSK3B (0.62) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL10789142 | 0.85 | GSK3B (0.62) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL11510574 | 0.83 | GSK3B (0.71) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL240086 | 0.83 | GSK3B (0.71) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL10788268 | 0.82 | GSK3B (0.59) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL220960 | 0.82 | GSK3B (0.69) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL11713734 | 0.82 | GSK3B (0.69) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL16938818 | 0.81 | MAPT (0.63) | GSK3BTSHRCES1CA1CA2 | |
| SCHEMBL279440 | 0.81 | MAPK1 (0.63) | GSK3BTSHRCES1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179832-B2 | Storage stable heat activated quaternary ammonium catalysts for epoxy cure | HENKEL AG & CO. KGAA (DE) | 2019-01-15 | — | — | US | claimed |
| EP-3131671-A1 | STORAGE STABLE HEAT ACTIVATED QUATERNARY AMMONIUM CATALYSTS FOR EPOXY CURE | Henkel AG & Co. KGaA (DE) | 2017-02-22 | — | — | EP | claimed |
| US-20170029558-A1 | STORAGE STABLE HEAT ACTIVATED QUATERNARY AMMONIUM CATALYSTS FOR EPOXY CURE | HENKEL AG & CO. KGAA (DE) | 2017-02-02 | — | — | US | claimed |
| WO-2015158774-A1 | STORAGE STABLE HEAT ACTIVATED QUATERNARY AMMONIUM CATALYSTS FOR EPOXY CURE | HENKEL AG & CO. KGAA (DE) | 2015-10-22 | — | — | WO | claimed |
| EP-2933019-A1 | Storage stable heat activated quaternary ammonium catalysts for epoxy cure | Henkel AG&Co. KGAA (DE) | 2015-10-21 | — | — | EP | claimed |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | claimed |
| US-20090137420-A1 | METHODS, COMPOUNDS AND COMPOSITIONS WITH GENOTYPE SELECTIVE ANTICANCER ACTIVITY | TRANSLATIONAL GENOMLES, RESEARCH INSTITUTE | 2009-05-28 | — | — | US | claimed |
| EP-1877352-A4 | METHODS, COMPOUNDS AND COMPOSITIONS WITH GENOTYPE SELECTIVE ANTICANCER ACTIVITY | TGEN (US) | 2009-01-21 | — | — | EP | claimed |
| EP-1877352-A2 | METHODS, COMPOUNDS AND COMPOSITIONS WITH GENOTYPE SELECTIVE ANTICANCER ACTIVITY | Tgen (US) | 2008-01-16 | — | — | EP | claimed |
| WO-2006113367-A2 | METHODS, COMPOUNDS AND COMPOSITIONS WITH GENOTYPE SELECTIVE ANTICANCER ACTIVITY | TGEN (US) | 2006-10-26 | — | — | WO | claimed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-10179832-B2 | Storage stable heat activated quaternary ammonium catalysts for epoxy cure | HENKEL AG & CO. KGAA (DE) | 2019-01-15 | — | — | US | disclosed |
| EP-3016951-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | GSK3B 2840/4885TSHR 562/4885CES1 2845/4885 |
| US-20090137420-A1 | METHODS, COMPOUNDS AND COMPOSITIONS WITH GENOTYPE SELECTIVE ANTICANCER ACTIVITY | TP53, MCL1, VHL | GSK3B 2142/4885TSHR 4773/4885CES1 1486/4885 |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | GSK3B 54/4885TSHR 3633/4885CES1 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.